Olaparib bei biochemischem Rezidiv des High-risk-Prostatakarzinoms nach Prostatektomie
Open Access
- 17 December 2024
- journal article
- research article
- Published by Springer Nature in Strahlentherapie und Onkologie
- Vol. 201 (3) , 343-345
Abstract
No abstract availableKeywords
Funding Information
- Universitätsklinikum Hamburg-Eppendorf (UKE)
This publication has 14 references indexed in Scilit:
- Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following ProstatectomyJAMA Oncology, 2024
- Preclinical patient‐derived modeling of castration‐resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient diseaseMolecular Oncology, 2023
- Rucaparib or Physician’s Choice in Metastatic Prostate CancerNew England Journal of Medicine, 2023
- Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate CancerNEJM Evidence, 2022
- 689TiP NRG Oncology’s GU007 (NADIR): A randomized phase II trial of niraparib with standard combination androgen deprivation therapy (ADT) and radiotherapy (RT) in high-risk prostate cancer (PC) (with initial phase I)Annals of Oncology, 2020
- Olaparib for Metastatic Castration-Resistant Prostate CancerNew England Journal of Medicine, 2020
- Non-BRCA DNA Damage Repair Gene Alterations and Response to the PARP Inhibitor Rucaparib in Metastatic Castration-Resistant Prostate Cancer: Analysis From the Phase II TRITON2 StudyClinical Cancer Research, 2020
- Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM MutationsEuropean Urology, 2019
- RETRACTED ARTICLE: Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancerScientific Reports, 2018
- Poly(ADP-Ribose) Polymerase Inhibition as a Model for Synthetic Lethality in Developing Radiation Oncology TargetsSeminars in Radiation Oncology, 2010